Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of VLA15 Lyme Disease Vaccine in Healthy Adults
NCT03010228Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jan 2017
- Primary completion
- Sep 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of VLA15 in Lyme disease (6 arms), sponsored by Pfizer. Primary endpoints: Rate of Serious Adverse Events at Day 84, Rate of Related Serious Adverse Events at Day 84 and 4 more. Started Jan 2017; status: completed.
02
Drugs
VLA15
03
Conditions
Lyme disease
Beyond the preview
Go deeper on NCT03010228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03010228.